Thousands protest against anti-immigrant riots in S. Africa

Updated 23 April 2015

Thousands protest against anti-immigrant riots in S. Africa

JOHANNESBURG, South Africa: Several thousand demonstrators marched through central Johannesburg on Thursday to protest against a spate of deadly attacks on immigrants, after further raids by the authorities on suspected gang hideouts.
Watched by police, crowds sang songs denouncing xenophobia and carried banners that read “We are all Africans” as migrant workers crowded balconies, shouting their support.
“This march sends an important message to the world, to Africans,” David Makhura, premier of Gauteng province, of which Johannesburg is the capital, told the demonstrators.
“We are going to defeat xenophobia like we defeated apartheid.
“We are here to make sure that South Africa is a country of peace for all.”
Soldiers were deployed in Johannesburg this week to aid police in raids on hostels housing South African men who are accused of targeting migrants from Zimbabwe, Malawi, Mozambique and other African countries.
At least seven people have been killed in three weeks of unrest that have revived memories of xenophobic bloodshed in 2008, when 62 people were killed.
“I am here to make a stand, to say ‘Not in my name’,” Zain Mayet, 20, one of the marchers, told AFP.
“Keeping quiet makes me as guilty as those who are committing violence.
“We are here to demonstrate that not everyone in South Africa is a criminal who attacks foreign nationals.”
UN chief Ban Ki-moon condemned the violence and called for “all efforts” to be made to avoid future attacks.
“He welcomes the public expressions of the many South Africans who have been calling for peaceful coexistence and harmony with foreign nationals,” Ban’s spokesman said in a statement.

Two people were arrested late Wednesday when police, backed by soldiers, stormed a workers’ hostel in the city’s crowded Alexandra township.
In total, over 300 people have been detained.
The unrest erupted in the port city of Durban about three weeks ago and later spread to Johannesburg, the economic capital.
Many immigrants have been forced to flee their homes and abandon their small shops as marauding mobs hunted down foreigners at night.
“Over 5,000 people from Malawi, Zimbabwe, Mozambique, Democratic Republic of Congo and Burundi still seek refuge in displacement camps,” Medecins Sans Frontieres (MSF — Doctors Without Borders) said in a statement.
“Injured Malawian and Zimbabwean men told medics that they are too afraid to openly seek medical treatment for their wounds and fractures for fear of further attack.”
More than 20 years since the end of apartheid, many South Africans believe the lack of opportunities for young blacks and a severe jobs shortage has led to deep frustration.
One Mozambican man was stabbed to death in Alexandra township last Saturday in scenes that provoked widespread outrage after the killing was captured in graphic newspaper photographs.
Alexandra, where Nelson Mandela lived as a young man, is one of the most troubled parts of Johannesburg and is located next to the upmarket business district of Sandton.
President Jacob Zuma has pledged to tackle anti-migrant sentiment in South Africa and to address deep-rooted problems behind the attacks.
“South Africans are not xenophobic,” he said Wednesday. “If we don’t deal with the underlying issues, it will come back.”
Zuma gave few details of government plans, but said the violence was driven by “criminal elements” as well as friction between foreigners and locals.
The president will hold meetings on Friday with leaders representing South Africa’s immigrant communities.
Regional relations have been strained by the attacks, with Zimbabwe, Malawi and Mozambique organizing for some worried citizens to return home.
Neighbouring Mozambique said more than 2,000 citizens had fled the violence.
Five buses also arrived back in Zimbabwe on Wednesday.


Indonesia begins human trials of anti-virus vaccine

Updated 12 August 2020

Indonesia begins human trials of anti-virus vaccine

  • The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday
  • The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines

JAKARTA: Indonesia is stepping up efforts to find a COVID-19 vaccine by launching human trials of a potentially effective drug amid criticism of its lacklustre handling of the pandemic and concerns about its plummeting economy.

The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday and is being conducted by the Padjadjaran University School of Medicine at six locations in Bandung, West Java province, where the university and the state-owned pharma company are based.

“The first day of the trial went well, with 20 volunteers in each of the six locations injected with the potential vaccine. We have no complaints so far, and we are preparing the second injection batch on Aug 14,” Iwan Setiawan, a spokesman for Bio Farma, told Arab News on Wednesday.

He added that the six-month trial would require the participation of 1,620 volunteers who were “in good health and had not tested positive” for the disease.

Ridwan Kamil, governor of West Java, Indonesia’s most populated province, is among the volunteers who have signed up for the trial.

The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines.

“The potential vaccine had gone through three trials; the pre-clinical, the clinical trial first phase and the second phase in China,” Bio Farma CEO Honesti Basyir said in a statement.

According to Basyir, Sinovac is one of the few institutions that have progressed to the third phase of the clinical trial from among hundreds of research institutions around the world that are developing the COVID-19 vaccine.

According to Oxford Business Group’s COVID-10 Economic Impact Assessment, there are more than 150 different vaccines that international researchers are working on. However, only 26 have reached the human trial stage so far.

Once the trials are concluded, Bio Farma will register the vaccine with the Food and Drug Supervisory Agency so that it can begin mass-production of the drug.

“We have prepared a production facility for the COVID-19 vaccine with a maximum capacity of 100 million dosages, and by the end of December this year we will have an increased production capacity to produce an additional 150 million dosages,” Basyir said.

President Joko Widodo oversaw the first injections to the batch of volunteers in one of the six locations and also toured Bio Farma’s production facility. 

“We hope this clinical trial would conclude in six months and so we can start producing the vaccine in January and vaccinate our people soon,” Widodo said.

State-Owned Enterprise Minister Erick Thohir, who is also the head of the COVID-19 mitigation and national economic recovery committee, said that Bio Farma was a well-established vaccine producer whose products were halal-compliant and used in 150 countries, including in the Middle East.

The collaboration with Sinovac is one of three vaccine-development projects that Indonesia is engaging in with foreign parties as it grapples with a surge in infections. At the same time, social restrictions and economic activities were eased. The other two projects are with South Korea’s Genexine and Norway’s Coalition for Epidemic, Preparedness and Innovation.

As of Wednesday, Indonesia had reported 130,718 infections with 1,942 new cases, 85,798 recoveries and 5,903 deaths, although experts suggest that the numbers could be higher due to the country’s low testing capacity.

Cases also surged in the capital Jakarta with workplaces emerging as the new infection clusters after thousands of employees returned to work recently.